Clinical trial
A Phase II Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Tolerability, Safety, Pharmacokinetics and Efficacy of Intravenous INO-1001 in High Risk Subjects Undergoing Cardiopulmonary Bypass for Coronary Revascularization and/or Valve Surgery.
NCT00271167 is registered in ClinicalTrials.gov with Inotek Pharmaceuticals Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Tolerability, Safety, Pharmacokinetics and Efficacy of Intravenous INO-1001 in High Risk Subjects Undergoing Cardiopulmonary Bypass for Coronary Revascularization and/or Valve Surgery.
- Lead sponsor
- Inotek Pharmaceuticals Corporation
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 31, 2005
- Completion date
- June 30, 2006
- Enrollment
- 162
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.